Medical Cannabis Market Size, Trends and Top Key Players
According to Towards Healthcare, the global medical cannabis market size was estimated at USD 14.34 billion in 2024 and is anticipated to reach around USD 52.23 billion by 2034, growing at a CAGR of 13.8% from 2025 to 2034. This growth is largely driven by the increasing demand for effective solutions in chronic pain management, alongside ongoing research into mental health and neurological conditions.
Global Outlook
The medical cannabis market encompasses various forms, including pharmaceutical cannabis, regulated herbal options, and unregulated products aimed at treating conditions like epilepsy. With a broad spectrum of offerings ranging from synthetic cannabinoids like Dronabinol and Sativex to plant-derived products from the USA and the Netherlands, this market is rapidly evolving.
Organizations such as the Therapeutic Goods Administration in Australia are facilitating access for medical practitioners to prescribe cannabis-based treatments under specific conditions. Notably, in August 2024, Ukraine launched its medical cannabis program, underscoring a trend that includes tighter regulations in Europe aimed at controlling production and distribution of cannabis-based therapies.
Market Opportunity
Recent breakthroughs in research have paved the way for cannabis to be recognized for its medical benefits, leading to a surge in acceptance and demand. As public perceptions shift and regulations evolve, researchers are investigating the substantial impacts of medical cannabis on conditions such as brain aging, anxiety, chronic pain, and endometriosis. This growing body of evidence presents significant opportunities for both investment and development in the medical cannabis sphere.
Key Growth Factors
In a groundbreaking initiative, University College London and Great Ormond Street Hospital are set to conduct double-blind randomized controlled trials starting October 2024, focusing on the combined effects of tetrahydrocannabinol and cannabidiol in treating epilepsy across different age groups. Positive outcomes from these trials can lead to expanded regulatory approvals for cannabis-based treatments, potentially enhancing their availability through systems like the National Health Service.
Market Restraint
Despite its growth potential, the medical cannabis market faces challenges, particularly regarding safety and efficacy questions that stem from existing clinical studies. Publicly funded research often grapples with logistical hurdles, funding limitations, and regulatory barriers, constraining the ability of clinicians to prescribe cannabis-based products and evaluate their long-term impacts as medical treatments.
Segmental Outlook
By Product Type
As of 2024, the dissolvable/powder segment leads the market due to the superior absorption and bioavailability of these forms. They are easy to consume and offer flexibility in dosing. Conversely, the oil segment is projected to grow the fastest during the forecast period, underscoring the versatility of cannabis oils in pharmaceuticals, cosmetics, and various industrial applications.
By Derivative
The cannabidiol segment is dominant due to its wide-ranging therapeutic applications, especially in treating neurological disorders and providing anti-inflammatory effects. Meanwhile, tetrahydrocannabinol is expected to see rapid growth attributed to its FDA-approved uses in chemotherapy-induced nausea and its therapeutic potential in various conditions.
By Route of Administration Type
The inhalation segment commands the market as it allows for targeted delivery and rapid therapeutic effects. However, the oral administration segment is poised for faster growth, thanks to cost-effectiveness and the variety of dosage forms that appeal to a broader range of patients.
By Application
In 2024, pain management was the leading application area for medical cannabis, as it provides significant relief for conditions like neuropathic pain and cancer pain. The segment focusing on neurological health is expected to exhibit the fastest growth, particularly due to the rising acknowledgement of cannabis’s benefits in treating conditions like Parkinson’s disease and epilepsy.
By Distribution Channel
The hospital pharmacy segment led the market in 2024 due to an increased focus on comprehensive patient care and treatment options. Online pharmacies, however, are forecasted to grow at the fastest rate as accessibility increases and telemedicine continues to improve patient engagement and adherence.
Geographical Outlook
North America
North American markets are at the forefront of medical cannabis, largely attributed to regulatory advances and heightened patient access. Notably, as of June 2025, multiple states and territories have established legal frameworks allowing medical cannabis use, promising a robust environment for growth in patient access and safety initiatives.
In a notable move, the U.S. Department of Justice proposed rescheduling cannabis as a Schedule III drug, reflecting its increasing recognition as a legitimate medical treatment.
Canada
Canada’s legislative landscape supports medical cannabis through strict regulations and a tracking system, ensuring safety and accessibility. Initiatives like the reimbursement policy for veterans demonstrate the government’s commitment to patient care within the framework of the Medical Cannabis Regulations.
Asia Pacific
The Asia Pacific region is set to surpass other markets in growth rate due to supportive governmental policies and the burgeoning legalization of medical cannabis. For instance, India’s Central Drugs Standard Control Organization is refining processes to facilitate cannabis import and export. Collaborative projects like the partnership between Somai Pharmaceuticals and Pacific Cannovation aim to establish Thailand as a global hub for medicinal cannabis.
Strategic Moves by Key Players
- In May 2025, Canopy Growth Corporation announced innovative products targeting the Canadian adult-use market, including high-THC flower and edibles.
- In August 2025, Green Thumb Industries reported a robust revenue growth, affirming their strong foothold in the market.
Medical Cannabis Market Companies
- Canopy Growth Corporation
- Aurora Cannabis Inc.
- Tilray Brands
- Cronos Group Inc.
- Green Thumb Industries
- Trulieve Cannabis Corp.
- Innovative Ind Props
- Cresco Labs
- Glass House Brands
- Curaleaf Holdings
- Jazz Pharmaceuticals plc
- GW Pharmaceuticals plc
- OrganiGram Holding Inc.
- HEXO Corp.
- Medical Marijuana, Inc
- Verano Holdings Corp
- TerrAscend Corp.
Segments Covered in the Report
By Product Type
- Dissolvable/Powder
- Oil
- Solids
- Ointments & Creams
By Derivative
- Cannabidiol
- Tetrahydrocannabinol
By Route of Administration
By Application
- Pain Management
- Neuropathic Pain
- Cancer
- Inflammatory Pain
- Neurological Health Management
- Mental Health Management
By Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
By Region
- North America
- Asia Pacific
- China
- Singapore
- Japan
- India
- South Korea
- Thailand
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Sweden
- Denmark
- Norway
- Latin America
- Middle East and Africa
- South Africa
- UAE
- Saudi Arabia
- Kuwait
Source: https://www.towardshealthcare.com/insights/medical-cannabis-market-size